Company Overview - Revvity, Inc. (RVTY) is a leading provider of health sciences solutions, technologies, and diagnostic services, headquartered in Waltham, Massachusetts, with a market cap of $10.3 billion [1] Stock Performance - RVTY shares have underperformed the broader market, declining 15% over the past year, while the S&P 500 Index has increased by nearly 12.3% [2] - In 2025, RVTY's stock fell 16.6%, contrasting with the S&P 500's 12.5% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7.5% year-to-date, RVTY's performance has been notably weaker [3] Financial Results - For Q3, RVTY reported revenue of $7 billion, reflecting a year-over-year increase of 2.2%, while adjusted EPS fell 7.8% to $1.18 [4] - Analysts project RVTY's EPS to grow marginally to $4.92 on a diluted basis for the current fiscal year ending in December [4] - RVTY has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [4] Analyst Ratings - Among 17 analysts covering RVTY, the consensus rating is a "Moderate Buy," consisting of nine "Strong Buy" ratings, one "Moderate Buy," and seven "Holds" [5] - Brandon Couillard from Wells Fargo maintained a "Hold" rating with a price target of $102, indicating a potential upside of 9.6% from current levels [6] - The mean price target of $113.07 suggests a 21.5% premium to RVTY's current price, while the highest price target of $135 indicates a potential upside of 45.1% [6]